Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation

Anticancer Research

Volumn 21, Issue 2 A, 2001, Pages 847-856

  Ibrahim, S ^a   Peggins, J ^a   Knapton, A ^a   Licht, T ^a   Aszalos, A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Daunorubicin; Drug classes; Multidrug resistance; P glycoprotein

Indexed keywords

ACEBUTOLOL; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE; DAUNORUBICIN; DEXTROPROPOXYPHENE; DIPHENHYDRAMINE; DIURETIC AGENT; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LABETALOL; LOPERAMIDE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; NADOLOL; PETHIDINE; PINDOLOL; PIROXICAM; PROPRANOLOL; QUINOLONE DERIVATIVE; RHODAMINE 123; TERFENADINE; TRIPROLIDINE; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT;

3T3 CELLS; 4-QUINOLONES; ADRENERGIC BETA-ANTAGONISTS; ANALGESICS; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CACO-2 CELLS; CELL LINE; CELLS, CULTURED; DAUNORUBICIN; DIURETICS; DOGS; FLOW CYTOMETRY; GENE EXPRESSION; HISTAMINE H1 ANTAGONISTS; HUMANS; MICE; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0035021840     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. Structure and expression of the human MDR (P-glycoprotein) gene family
3. Functional involvement of Pglycoprotein in bloodbrain barrier
4. Expression and function of P-glycoprotein (MDR1 gene product) in normal and malignant tissues
5. Clinical trials of agents that reverse multidrug resistance
6. Transporting therapeutics across the blood-brain barrier
7. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
8. High level expression of the multidrug resistance (MDR1) gene in normal bladder urothelium: A potential involvement in protection against carcinogens
9. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
10. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
11. Clinical trials of modulation of multidrug resistance
12. Regulatory considerations for preclinical development of anticancer drugs
13. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
14. P-glycoprotein in the blood brain barrier of mice influences the activity of many drugs
15. Pharmacokinetic drug interactions
16. Pharmacokinetic Drug Interactions of commonly used anticancer drugs
17. The elderly and drug interactions
18. Differentiation between specific and nonspecific effects related to P-glycoprotein inhibition in immortalized rat brain endothelial cells
19. A retrovirus carrying MDR1 cDNA confers multiple drug resistance and polarized expression of P-glycoprotein in MDCK cells
20. Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporter
21. Studies of Plasmodium Falciparum cytoadherence using immortalized human brain capillary endothelial cells
22. Construction of MDR1 vectors for gene therapy
23. Selection and maintenance of multidrug-resistant cells
24. MDR1/Pglycoprotein function I. Effect of hypotonicity and inhibitors on rhodamine123 exclusion
25. The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multidrug transporter
26. P-glycoprotein (Pgp) mediated efflux in Caco-2 cell monolyers: The influance of culturing conditions and drug exposure on Pgp expression levels
27. Influence of antipsychotic, antiemetic, and Ca2+ channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation
28. The pharmacokinetics of acetazolamide during CAPD
29. Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine
30. HPLC determination of benzthiazide in biologic material
31. Bioavailability in man of atenolol and chlorthalidone from a combination formulation
32. Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer
33. Pharmacokinetics of orally administered hydroflumethiazide in man
34. Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers
35. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice
36. Influence of itraconazole on the pharmaco-kinetics and electrocardiographic effects of astemizole
37. Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly
38. Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives
39. Pharmacokinetics of oral and transdermal triprolidine
40. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations
41. Pharmacokinetics of acebutolol enantiomers in humans
42. Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients
43. Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: Assessment using stereospecific and nonstereospecific assays
44. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage
45. Relative bioavailability of oral forms oftenoxicam
46. Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules)